{"entity":{"id":"tigit-blockade","kind":"technology","name":"TIGIT blockade","aka":[],"tldr":"Antibodies against TIGIT, a brake on T cells and natural killer cells, tested alongside PD-L1 drugs; the biggest lung cancer trials so far have failed.","summary":"TIGIT is an inhibitory receptor on T and natural killer cells that competes with the activating receptor CD226 for the ligand CD155. Tiragolumab (Roche) reached phase 3 with atezolizumab after promising phase 2 results in lung cancer, but the SKYSCRAPER programme did not improve survival, and several rivals paused development. Fc-active and Fc-silent antibodies, and combinations in other tumours, are still being tested.","status":"phase-3","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/TIGIT","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/TIGIT"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":["immunotherapy"],"technologies":[],"targets":["tigit"],"drugs":["tiragolumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"principle":"Monoclonal antibodies bind TIGIT to stop it engaging CD155, freeing CD226 co-stimulation; Fc-active versions may also deplete regulatory T cells.","strengths":["Complements PD-1/PD-L1 blockade mechanistically","Well tolerated in trials"],"limitations":["Phase 3 lung cancer trials negative","Benefit, if any, confined to undefined subgroups","Fc-format questions unresolved"]},"route":"/technologies/tigit-blockade/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"target":[{"id":"nectin2","kind":"target","name":"CD112 (nectin-2)","route":"/targets/nectin2/"},{"id":"pvr","kind":"target","name":"CD155 (PVR)","route":"/targets/pvr/"},{"id":"cd96","kind":"target","name":"CD96","route":"/targets/cd96/"},{"id":"pvrig","kind":"target","name":"PVRIG (CD112R)","route":"/targets/pvrig/"},{"id":"tigit","kind":"target","name":"TIGIT","route":"/targets/tigit/"}],"drug":[{"id":"tiragolumab","kind":"drug","name":"Tiragolumab","route":"/drugs/tiragolumab/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"trial":[{"id":"nct05904886","kind":"trial","name":"A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocell","route":"/trials/nct05904886/"},{"id":"nct05645692","kind":"trial","name":"A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer","route":"/trials/nct05645692/"},{"id":"nct05009069","kind":"trial","name":"A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer","route":"/trials/nct05009069/"},{"id":"nct04665856","kind":"trial","name":"Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer","route":"/trials/nct04665856/"}]}}